Expanding TAVI to Low and Intermediate Risk Patients
TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durabili...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2018.00092/full |
| _version_ | 1818683233184776192 |
|---|---|
| author | Lisa Voigtländer Moritz Seiffert Moritz Seiffert |
| author_facet | Lisa Voigtländer Moritz Seiffert Moritz Seiffert |
| author_sort | Lisa Voigtländer |
| collection | DOAJ |
| description | TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durability—need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines. |
| first_indexed | 2024-12-17T10:31:29Z |
| format | Article |
| id | doaj.art-8df93c64b6ca4d39a845d968bcc88c7c |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-17T10:31:29Z |
| publishDate | 2018-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-8df93c64b6ca4d39a845d968bcc88c7c2022-12-21T21:52:30ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2018-07-01510.3389/fcvm.2018.00092380580Expanding TAVI to Low and Intermediate Risk PatientsLisa Voigtländer0Moritz Seiffert1Moritz Seiffert2Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, GermanyDepartment of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, GermanyPartner site Hamburg/Kiel/Lübeck, DZHK, German Centre for Cardiovascular Research, Hamburg, GermanyTAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durability—need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.https://www.frontiersin.org/article/10.3389/fcvm.2018.00092/fullTAVITAVRintermediate risklow riskaortic valve stenosis |
| spellingShingle | Lisa Voigtländer Moritz Seiffert Moritz Seiffert Expanding TAVI to Low and Intermediate Risk Patients Frontiers in Cardiovascular Medicine TAVI TAVR intermediate risk low risk aortic valve stenosis |
| title | Expanding TAVI to Low and Intermediate Risk Patients |
| title_full | Expanding TAVI to Low and Intermediate Risk Patients |
| title_fullStr | Expanding TAVI to Low and Intermediate Risk Patients |
| title_full_unstemmed | Expanding TAVI to Low and Intermediate Risk Patients |
| title_short | Expanding TAVI to Low and Intermediate Risk Patients |
| title_sort | expanding tavi to low and intermediate risk patients |
| topic | TAVI TAVR intermediate risk low risk aortic valve stenosis |
| url | https://www.frontiersin.org/article/10.3389/fcvm.2018.00092/full |
| work_keys_str_mv | AT lisavoigtlander expandingtavitolowandintermediateriskpatients AT moritzseiffert expandingtavitolowandintermediateriskpatients AT moritzseiffert expandingtavitolowandintermediateriskpatients |